

## **Scientific References for The UltraMind Solution**

1. Demyttenaere, K., et al. WHO World Mental Health Survey Consortium. 2004. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization, World Mental Health Surveys. *JAMA* 21:2581–90.
2. World Health Initiative on Depression in Public Health. [www.who.int/mental\\_health/management/depression/depressioninph/en/](http://www.who.int/mental_health/management/depression/depressioninph/en/)
3. Mental Health:A Report of the Surgeon General. Rockville,MD.U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health, 1999.
4. Belfer, M. L. 2008. Child and adolescent mental disorders: the magnitude of the problem across the globe. *J Child Psychol Psychiatry* 49 (3):226–36.
5. An Unhealthy America, Economic Burden of Chronic Disease (October 2007).
6. <http://www.milkeninstitute.org/publications/publications.taf?function=detail&ID=38801020&cat=ResRep>
7. Serafetinides, E. A. 1971. Cost of psychiatric illness versus cost of psychiatric research. *Am J Psychiatry* 148:951.
8. Froehlich, T. E., et al. 2007. Prevalence, recognition, and treatment of Attention-Deficit/Hyperactivity Disorder in a national sample of U.S. children. *Arch PediatrAdolesc Med* 161 (9):857–64.
9. Zuvekas, S. H., B.Vitiello,G. S. Norquist. 2006. Recent trends in stimulant medication use among U.S. children. *Am J Psychiatry* 63 (4):579–85.
10. Wazana,A., M. Bresnahan, and J. Kline. 2007.The autism epidemic: Fact or artifact? *J Am Acad Child Adolesc Psychiatry* 46 (6):721–30.
11. Grizzle, K. L. 2007. Developmental dyslexia. *Pediatr Clin North Am* 54 (3):507–523, vi.
12. Hibbeln, J. R. 2007. From homicide to happiness—a commentary on omega-3 fatty acids in human society. Cleave Award Lecture. *Nutr Health* 19 (1–2):9–19.

13. Tiemeir, H., et al. 2002. Vitamin B12 folate, and homocysteine in depression: the Rotterdam Study. *Am J Psychiatry* 159 (12):2099–101.
14. Davis, J.D., and G.Tremont. 2007. Neuropsychiatric aspects of hypothyroidism and treatment reversibility. *Minerva Endocrinol* 32 (1):49–65. Review.
15. Zachi, E. C., et al. 2007. Neuropsychological dysfunction related to earlier occupational exposure to mercury vapor. *Braz J Med Biol Res* 40 (3):425–33.
16. Paulose-Ram, R., et al. 2007. Trends in psychotropic medication use among U.S. adults. *Pharmacoepidemiol Drug Saf* 16 (5):560–70.
17. Papakostas, G. I. 2007. Limitations of contemporary antidepressants: tolerability. *J Clin Psychiatry* 68 Suppl 10:11–7.
18. Turner, E. H., et al. 2008. Selective publication of antidepressant trials and its influence on apparent efficacy. *N Engl J Med* 358 (3):252–60.
19. Adi-Japha, E., et al. 2007. ADHD and dysgraphia: underlying mechanisms. *Cortex* 43 (6):700–9.
20. McCann, D., A. Barrett, and A. Cooper. 2007. Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blinded, placebo-controlled trial. *Lancet*.
21. Stevenson, J. 2006. Dietary influences on cognitive development and behaviour in children. *Proc Nutr Soc* 65 (4):361–65.
22. Sinn, N. 2007. Physical fatty acid deficiency signs in children with ADHD symptoms. *Prostaglandins Leukot Essent Fatty Acids*.
23. Mousain-Bosc, M., et al. 2006. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. I. Attention deficit hyperactivity disorders. *Magnes Res* 19 (1):46–52.
24. Randle, H.W., and R. K.Winkelmann. 1980. Pityriasis rubra pilaris and celiac sprue with malabsorption. *Cutis* 25 (6):626–27.
25. Holick, M. F. 2007. Vitamin D deficiency. *N Engl J Med* 357 (3):266–81. Review.

26. Wintergerst, E. S., S. Maggini, and D. H. Hornig. Contribution of selected vitamins and trace elements to immune function. *Ann Nutr Metab* (2007) 51 (4):301–23.
27. Altura, B. M., and B.T. Altura. 2001. Tension headaches and muscle tension: Is there a role for magnesium? *Med Hypotheses* 57 (6):705–13.
28. Vargas, D. L., et al. 2005. Neuroglial activation and neuroinflammation in the brain of patients with autism. *Ann Neurol* 57 (1):67–81.
29. Lenoir, M., et al. 2007. Intense sweetness surpasses cocaine reward. *PLoS ONE* 2 (1):e698.
30. Drisko, J., et al. 2006. Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics. *J Am Coll Nutr* 25 (6):514–22.
31. Sedghizadeh, P. P., et al. 2002. Celiac disease and recurrent aphthous stomatitis: A report and review of the literature. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 94 (4):474–78.
32. Macdonald, T.T., and G. Monteleone. 2005. Immunity, inflammation, and allergy in the gut. *Science* 307 (5717):1920–1925.
33. Cheuk, D. K., and V. Wong. 2006. Attention-deficit hyperactivity disorder and blood mercury level: A case-control study in Chinese children. *Neuropediatrics* 37 (4):234–40.
34. Banerjee, T.D., F. Middleton, and S.V. Faraone. 2007. Environmental risk factors for attention-deficit hyperactivity disorder. *Acta Paediatr* 96 (9):1269–1274.
35. Braun, J. M., et al. 2006. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. *Environ Health Perspect* 114 (12):1904–1909.
36. Institute for Functional Medicine. *Textbook of Functional Medicine*. Gig Harbor, Wa.: Institute for Functional Medicine, 2005.
37. Laing, R. D. *The Voice of Experience* (New York: Pantheon, 1982).
38. Rosenhan, D. L. 1973. On being sane in insane places. *Science* 179 (70): 250–58.
39. Laplace, Pierre-Simon. *1749–1827: A Life in Exact Science*, Charles Coulston Gillispie (Princeton: Princeton University Press, 2000).

40. Green, P. H., and B. Jabri. 2003. Coeliac disease. *Lancet* 362 (9381):383–91. Review.
41. Farrell, R. J., and C. P. Kelly. 2002. Celiac sprue. *N Engl J Med* 346 (3):180–88. Review.
42. Bushara, K. O. 2005. Neurologic presentation of celiac disease. *Gastroenterology* 128 (4 Suppl 1):S92–97. Review.
43. Millward, C., et al. 2004. Gluten- and casein-free diets for autistic spectrum disorder. *Cochrane Database Syst Rev* 2:CD003498. Review.
44. Grosjean, B., and G. E. Tsia. 2007. NMDA neurotransmission as a critical mediator of borderline personality disorder. *J Psychiatry Neurosci* 32 (2):103–15. Review.
45. Niederhofer, H., and K. Pittschlieler. 2006. A preliminary investigation of ADHD symptoms in persons with celiac disease. *J Atten Disord* 10 (2):200–4.
46. Martin, A., and D. Leslie. 2003. Trends in Psychotropic Medication Costs for Children and Adolescents, 1997–2000. *Arch Pediatr Adolesc Med* 157: 997–1004.
47. Scheffler, R. M., et al. 2007. The global market for ADHD medications. *Health Aff* 26 (2):450–57.
48. Bhatara, V., et al. 2004. National trends in concomitant psychotropic medication with stimulants in pediatric visits: Practice versus knowledge. *Atten Disord* 7 (4):217–26.
49. Kaufman, D. W., et al. 2002. Recent patterns of medication use in the ambulatory adult population of the United States. The Slone Survey. *JAMA* 287:337–44.
50. Herbert, M. R. 2005. Autism, a brain disorder, or a disorder that affects the brain? *Clin Neuropsychiatry* 2 (6):354–79.
51. U.C. Davis work, MIND institute work, Pardo C., Johns Hopkins.
52. Selkoe, D. J., American College of Physicians; American Physiological Society. 2004. Alzheimer's disease: mechanistic understanding predicts novel therapies. *Ann Intern Med* 140 (8):627–38. Review.

53. Yaffe, K., et al. 2004. The metabolic syndrome, inflammation, and risk of cognitive decline. *JAMA* 292 (18):2237–2242.
54. Ehninger, D., and G. Kempermann. 2007. Neurogenesis in the adult hippocampus. *Cell Tissue Res*.
55. Johnson, R. J., et al. 2007. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. *Am J Clin Nutr* 86 (4):899–906.
56. George A. Bray, S. J. Nielsen, and B. M. Popkin. 2004. Consumption of highfructose corn syrup in beverages may play a role in the epidemic of obesity. *Am. J. Clinical Nutrition* 79:537–43.
57. Lenoir, M., et al. 2007. Intense sweetness surpasses cocaine reward. *PLoS ONE* 2 (1):e698.
58. Holford, P. *Optimum Nutrition for the Mind* (Laguna Beach: Basic Health Publications, 2004).
59. Morris, M. C., et al. 2003. Dietary fats and the risk of incident Alzheimer disease. *Arch Neurol* 60 (2):194–202. *Ibid.*, 194–200.
60. Trejo, J. L., et al. 2002. Sedentary life impairs self-reparative processes in the brain: The role of serum insulin-like growth factor-I. *Rev Neurosci* 13 (4):365–74. Review.
61. Vaynman, S., and F. Gomez-Pinilla. 2006. Revenge of the “sit”: How lifestyle impacts neuronal and cognitive health through molecular systems that interface energy metabolism with neuronal plasticity. *J Neurosci Res* 84 (4):699–715. Review.
62. Cotman, C.W., N. C. Berchtold, and L. A. Christie. 2007. Exercise builds brain health: Key roles of growth factor cascades and inflammation. *Trends Neurosci* 30 (9):464–72. Epub August 31, 2007.
63. Blumenthal, J. A., et al. 2007. Exercise and pharmacotherapy in the treatment of major depressive disorder. *Psychosom Med* 69 (7):587–96.
64. Swaab, D. F., A. M. Bao, and P. J. Lucassen. 2005. The stress system in the human brain in depression and neurodegeneration. *Ageing Res Rev* 4(2):141–94. Review.
65. Doraiswamy, P. M., and G. L. Xiong. 2007. Does meditation enhance cognition and brain longevity? *Ann NY Acad Sci*.

66. Gilliland, K., and D. Andress. 1981. Ad lib caffeine consumption, symptoms of caffeinism, and academic performance. *Am J Psychiatry* 138 (4):512–14.
67. O'Keefe, J. H., K.A. Bybee, and C. J. Lavie. 2007. Alcohol and cardiovascular health: the razor-sharp double-edged sword. *J Am Coll Cardiol* 50 (11):1009–1014. Review.
68. Anttila, T., et al. 2004. Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: A prospective population based study. *BMJ* 329 (7465):539.
69. Mukamal, K. J., et al. 2003. Prospective study of alcohol consumption and risk of dementia in older adults. *JAMA* 289 (11):1405–1413.
70. Volkow, N. D., et al. 1992. Decreased brain metabolism in neurologically intact healthy alcoholics. *Am J Psychiatry* 149 (8):1016–1022.
71. Brunnemann, K., and D. Hoffmann. 1991. Analytical studies on tobacco-specific N-nitrosamines in tobacco and tobacco smoke. *Crit Rev Toxicol* 21:235–40.
72. Pergadia, M., et al. 2004. Double-blind trial of the effects of tryptophan depletion on depression and cerebral blood flow in smokers. *Addict Behav* 29 (4):665–71.
73. De Mendelssohn, A. S. Kasper, and J. Tauscher. 2004. [Neuroimaging in substance abuse disorders] *Nervenarzt* 75 (7):651–62. Review.
74. Littarru, G. P., and P. Langsjoen. 2007. Coenzyme Q10 and statins: Biochemical and clinical implications. *Mitochondrion* 7 Suppl:S168–74. Epub March 27, 2007. Review.
75. Valuck, R. J., and J. M. Ruscin. 2004. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. *J Clin Epidemiol* 57 (4):422–28.
76. Dial, S., et al. 2005. Use of gastric acid-suppressive agents and the risk of community acquired *Clostridium difficile*-associated disease. *JAMA* (23):2989–2995.
77. Yang, Y. X., et al. 2006. Long-term proton pump inhibitor therapy and risk of hip fracture. *JAMA* 296 (24):2947–2953.

78. Ruscin, J. M., R. L. Page, and R. J. Valuck. 2002. Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. *Ann Pharmacother* 36 (5):812–16.
79. Laine, L., et al. 2000. Review article: potential gastrointestinal effects of longterm acid suppression with proton pump inhibitors. *Aliment Pharmacol Ther* 14 (6):651–68. Review.
80. Atkuri, K. R., J. J. Mantovani, and L. A. Herzenberg. 2007. N—Acetylcysteine—a safe antidote for cysteine/glutathione deficiency. *Curr Opin Pharmacol* 7 (4):355–59. Epub June 29, 2007.
81. Ross, E. A., N. J. Szabo, and I. R. Tebbett. 2000. Lead content of calcium supplements. *JAMA* 284 (11):1425–1429.
82. Thompson, W. W., et al. 2007. Vaccine Safety Datalink Team. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. *N Engl J Med* 357 (13):1281–1292.
83. Deppisch, L. M., et al. 1999. Andrew Jackson's exposure to mercury and lead: Poisoned president? *JAMA* 282 (6):569–71.
84. Guzzi, G., et al. 2006. Dental amalgam and mercury levels in autopsy tissues: Food for thought. *Am J Forensic Med Pathol* 27 (1):42–45.
85. Harris, H. H., et al. 2008. Migration of mercury from dental amalgam through human teeth. *J Synchrotron Radiat* 15 (Pt 2):123–28.
86. Schober, S. E., et al. 2003. Blood mercury levels in US children and women of childbearing age, 1999–2000. *JAMA* 289 (13):1667–1674.
87. [www.cfsan.fda.gov/~acrobat/hgstak56.pdf](http://www.cfsan.fda.gov/~acrobat/hgstak56.pdf)
88. Cory-Slechta, D. A. 2005. Studying toxicants as single chemicals: Does this strategy adequately identify neurotoxic risk? *Neurotoxicology* 26 (4):491–510. Review.
89. [www.archive.ewg.org/reports/bodyburden2/execsumm.php](http://www.archive.ewg.org/reports/bodyburden2/execsumm.php)
90. [www.vm.cfsan.fda.gov/~dms/eafus.html](http://www.vm.cfsan.fda.gov/~dms/eafus.html).
91. Alavanja, M. C., J. A. Hoppin, and F. Kamel. 2004. Health effects of chronic pesticide exposure: Cancer and neurotoxicity. *Annu Rev Public Health* 25:155–97. Review.

92. Curl, C. L., R. A. Fenske, and K. Elgethun. 2003. Organophosphorus pesticide exposure of urban and suburban preschool children with organic and conventional diets. *Environ Health Perspect* 111 (3):377–82.
93. Roberts, E. M., et al. 2007. Maternal residence near agricultural pesticide applications and autism spectrum disorders among children in the California Central Valley. *Environ Health Perspect* 115 (10):1482–1489.
94. Grandjean, P., et al. 2006. Pesticide exposure and stunting as independent predictors of neurobehavioral deficits in Ecuadorian school children. *Pediatrics* 117 (3):e546–56.
95. McCann, D., et al. 2007. Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: A randomised, double-blinded, placebo-controlled trial. *Lancet* 370 (9598):1560–67.
96. Wang, B. L., et al. 2007. Unmetabolized VOCs in urine as biomarkers of low level exposure in indoor environments. *J Occup Health* 49 (2):104–10.
97. Uzun, N., and Y. Kendirli. 2005. Clinical, socio-demographic, neurophysiological and neuropsychiatric evaluation of children with volatile substance addiction. *Child Care Health Dev* 31 (4):425–32.
98. Shoemaker, R.C., and D. E. House. 2006. Sick building syndrome (SBS) and exposure to water-damaged buildings: Time series study, clinical trial and mechanisms. *Neurotoxicol Teratol* 28 (5): 573–88. Epub August 7, 2006.
99. Campbell, A.W., et al. 2003. Neural autoantibodies and neurophysiologic abnormalities in patients exposed to molds in water-damaged buildings. *Arch Environ Health* 58 (8):464–74.
100. Rea, W. J., et al. 2003. Effects of toxic exposure to molds and mycotoxins in building-related illnesses. *Arch Environ Health* 58 (7):399–405.
101. Bellinger, D. C. 2007. Children's cognitive health: The influence of environmental chemical exposures. *Altern Ther Health Med* 13 (2):S140–44. Review.
102. Needleman, H. L., and C. A. Gatsonis. 1990. Low-level lead exposure and the IQ of children. A meta-analysis of modern studies. *JAMA* 263 (5):673–78.

103. Needleman, H. L., et al. 1990. The long-term effects of exposure to low doses of lead in childhood. An 11-year follow-up report. *N Engl J Med* 322 (2):83–88.
104. Canfield, R. L., et al. 2003. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. *N Engl J Med* 348 (16):1517–1526.
105. Stewart, W. F., and B. S. Schwartz. 2007. Effects of lead on the adult brain: A 15-year exploration. *Am J Ind Med* 50 (10):729–39.
106. Menke, A., et al. 2006. Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. *Circulation* 114 (13):1388–1394.
107. Romano, C., and M. L. Grossi-Bianchi. 1968. Aphasia and dementia in childhood chronic lead encephalopathy: A curable form of acquired mental impairment. *Panminerva Med* 10 (11):448–50.
108. Choi, B. H. 1989. The effects of methylmercury on the developing brain. *Prog Neurobiol* 32 (6):447–70. Review.
109. Krewski, D., et al. 2007. Recent advances in research on radiofrequency fields and health: 2001–2003. *J Toxicol Environ Health B Crit Rev* 10 (4):287–318. Review.
110. Feychting, M. F., et al. 2003. Occupational magnetic field exposure and neurodegenerative disease. *Epidemiology* 14 (4):413–19; Discussion, 427–28.
111. Ahlbom, A. 2001. Neurodegenerative diseases, suicide and depressive symptoms in relation to EMF. *Bioelectromagnetics Suppl* 5:S132–43.
112. Freeman, M. P., et al. 2006. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. *J Clin Psychiatry* 67 (12):1954–1967. Review.
113. Hibbeln, J. R., L. R. Nieminen and W. E. Lands. 2004. Increasing homicide rates and linoleic acid consumption among five Western countries, 1961–2000. *Lipids* 39 (12):1207–1213.
114. Gesch, C. B., et al. 2002. Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners: Randomised, placebo-controlled trial. *Br J Psychiatry* 181:22–28.

115. Freeman, M. P. 2006. Omega-3 fatty acids and perinatal depression: a review of the literature and recommendations for future research. *Prostaglandins Leukot Essent Fatty Acids* 75 (4–5):291–97.
116. Richardson, A. I. 2004. Long-chain polyunsaturated fatty acids in childhood developmental and psychiatric disorders. *Lipids* 39 (12):1215–1222. Review.
117. Megson, M.N. 2000. Is autism a G-alpha protein defect reversible with natural vitamin A? *Med Hypothesis* 54 (6):979–83.
118. Parker, G., et al. 2006. Omega-3 fatty acids and mood disorders. *Am J Psychiatry* (2006) 163 (6):969–78. Review. Erratum in *Am J Psychiatry* 163 (10):1842.
119. Crook, T. H., et al. 1997. Effects of phosphatidylserine in age-associated memory impairment. *Neurology* 41 (5):644–49.
120. Hellhammer, J., et al. 2004. Effects of soy lecithin phosphatidic acid and phosphatidylserine complex (PAS) on the endocrine and psychological responses to mental stress. *Stress* 7 (2):119–26.
121. Kidd, P. M. 1999. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. *Altern Med Rev* 4 (3):144–61. Review.
122. Shaw, P., et al. 2007. Polymorphisms of the dopamine D4 receptor, clinical outcome, and cortical structure in attention-deficit/hyperactivity disorder. *Arch Gen Psychiatry* 64 (8):921–31.
123. Nyman, E. S., et al. 2007. ADHD candidate gene study in a population-based birth cohort: Association with DBH and DRD2. *J Am Acad Child Adolesc Psychiatry* 46 (12):1614–1621.
124. Sharma, A., et al. 1999. D4 dopamine receptor-mediated phospholipid methylation and its implications for mental illnesses such as schizophrenia. *Mol Psychiatry* 4 (3):235–46.
125. Das, U.N. 2008. Folic acid and polyunsaturated fatty acids improve cognitive function and prevent depression, dementia, and Alzheimer's disease. But how and why. *Prostaglandins Leukot Essent Fatty Acids* 78 (1):11–19.

126. Deijen, J.B. et al. 1999. Tyrosine improves cognitive performance and reduces blood pressure in cadets after one week of a combat training course. *Brain Res Bull* 48 (2):203–9.
127. Delgado, P. L., et al. 1990. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. *Arch Gen Psychiatry* 47 (5):411–18.
128. Coppen, A., and C. Bolander-Gouaille. 2005. Treatment of depression: time to consider folic acid and vitamin B12. *J Psychopharmacol* 19 (1):59–65. Review.
129. Roberts, S. H., et al. 2007. IT. Folate Augmentation of Treatment—Evaluation for Depression (FolATED); Protocol of a randomized controlled trial. *BMC Psychiatry* 7 (1):65.
130. Tiihonen, J., et al. 2006. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. *Arch Gen Psychiatry* 63 (12):1358–1367.
131. Abdou, A. M., et al. 2006. Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans. *Biofactors* 26 (3):201–8.
132. El Idrissi, A., et al. 2003. Prevention of epileptic seizures by taurine. *Adv Exp Med Biol* 526:515–25.
133. Courtney, C., et al. 2004. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. *Lancet* 363 (9427):2105–2115.
134. Hampl, J. S., C.A. Taylor, and C. S. Johnston. 2004. Vitamin C deficiency and depletion in the United States: the Third National Health and Nutrition Examination Survey, 1988 to 1994. *Am J Public Health* 94 (5):870–75.
135. Noble, J. M., A. Mandel, and M. C. Patterson. 2007. Scurvy and rickets masked by chronic neurologic illness: revisiting “psychologic malnutrition.” *Pediatrics* 119 (3):e783–90.
136. Ames, B.N. 2004. A role for supplements in optimizing health: the metabolic tuneup. *Arch Biochem Biophys* 423 (1):227–34. Review.
137. Kaplan, B. J. et al. 2007. Vitamins, minerals, and mood. *Psychol Bull* 133 (5):747–60.

138. Seshadri, S., et al. 2002. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. *N Engl J Med* 346 (7):476–83.
139. Ames, B. 2002. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased km): relevance to genetic disease and polymorphisms. *Am J Clin Nutr* 75:616–58.
140. Fairfield, K. 2002. Vitamins for chronic disease prevention in adults, scientific review. *JAMA* 287:3116–3126.
141. Vasquez, A. 2004. The clinical importance of vitamin D (cholecalciferol): A paradigm shift with implications for all health care providers, alternative therapies.
142. Holick, M. 2004. Vitamin D: importance in the prevention of cancers, type 1 diabetes,
143. heart disease and osteoporosis. *Am J Clin Nutr* 79:362–71.
144. Heaney, R. 2003. Long-latency deficiency disease: insights from calcium and vitamin D. *Am J Clin Nutr* 78:912–19.
145. Mischoulon, D., and M. F. Raab. 2007. The role of folate in depression and dementia. *J Clin Psychiatry* 68 Suppl 10:28–33. Review.
146. James, S. J., et al. 2004. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. *Am J Clin Nutr* 80 (6):1611–17.
147. Triantafyllou, N. I., et al. 2007. Folate and vitamin B12 levels in levodopa-treated Parkinson's disease patients: Their relationship to clinical manifestations, mood and cognition. *Parkinsonism Relat Disord*.
148. Reif, A., B. Pfulmann, and K. P. Lesch. 2005. Homocysteinemia as well as methylenetetrahydrofolate reductase polymorphism are associated with affective psychoses. *Prog Neuropsychopharmacol Biol Psychiatry* (7):1162–1168.
149. Herbert, V. 1962. Experimental nutritional folate deficiency in man. *Trans Assoc Am Physicians* 75:307–20.
150. Tolmunen, T., et al. 2007. Dietary folate and depressive symptoms are associated in middle-aged Finnish men. *J Nutr* 133 (10):3233–3236.

151. Penninx, B.W., et al. 2000. Vitamin B(12) deficiency and depression in physically disabled older women: Epidemiologic evidence from the Women's Health and Aging Study. *Am J Psychiatry* 157 (5):715–21.
152. Papakostas, G. I., et al. 2004. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. *J Clin Psychiatry* 65 (8):1090–1095.
153. Alpert, J. E., et al. 2002. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. *Ann Clin Psychiatry* 14 (1):33–38.
154. Corrada, M. M., C. H. Kawas, and J. Hallfrisch. 2005. Reduced risk of Alzheimer's disease with high folate intake: the Baltimore Longitudinal Study of Aging. *Alzheimer's and Dementia* 1:11–18.
155. Clarke, R., et al. 2007. Low vitamin B-12 status and risk of cognitive decline in older adults. *Am J Clin Nutr.* 86 (5):1384–1391.
156. Waly, M., et al. 2004. Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal. *Mol Psychiatry* 9 (4):358–70.
157. Gerrior, S., and L. Bente. 2007. "Nutrient Content of the U.S. Food Supply, 1909–94." U.S. Department of Agriculture, Center for Nutrition Policy and Promotion. Home Economics Report No. 53.
158. Alpaslan, M., and H. Gunduz. 2000. The effects of growing conditions on oil content, fatty acid composition and tocopherol content of some sunflower varieties produced in Turkey. *Die Nahrung* (Germany): 44 (6):434–7.
159. Composition of Foods: Raw, Processed, Prepared. USDA National Nutrient Database for Standard Reference, Release 15. U.S. Department of Agriculture, Agricultural Research Service, Beltsville Human Nutrition Research Center, Nutrient Data Laboratory (2002), [www.ars.usda.gov](http://www.ars.usda.gov).
160. Wilkins, C. H., et al. 2006. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. *Am J Geriatr Psychiatry* 14 (12):1032–40. Gloth, F. M. III, W. Alam, and B. Hollis. 1999. Vitamin D vs. broad spectrum phototherapy in the treatment of seasonal affective disorder. *J Nutr Health Aging* 3 (1):5–7.

162. Cannell, J. J. 2008. Autism and vitamin D. *Med Hypotheses* 70 (4):750–59.
163. Autier, P., and S. Gandini. 2007. Vitamin D supplementation and total mortality: a metaanalysis of randomized controlled trials. *Arch Intern Med* 167 (16):1730–1737. Review.
164. Holick, M. F. 2006. Vitamin D deficiency. *N Engl J Med* 357 (3):266–81. Review.
165. Holick, M. 2004. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers and cardiovascular disease. *Am J Clin Nutr* (80) suppl: 1678S–1688S.
166. Tong, G. M., and R. K. Rude. 2005. Magnesium deficiency in critical illness. *J Intensive Care Med* 20 (1):3–17. Review.
167. [www.who.int/publications/cra/chapters/volume1/0257–0280.pdf](http://www.who.int/publications/cra/chapters/volume1/0257–0280.pdf)
168. Nowak, G., B. Szewczyk, and A. Pilc. 2005. Zinc and depression. An update. *Pharmacol Rep* 57 (6):713–18. Review.
169. Heleniak, E. P., and S.W. Lamola 1986. A new prostaglandin disturbance syndrome in schizophrenia: delta-6-pyroluria. *Med Hypotheses* 19 (4):333–38. Review.
170. Hoffer, A., and M. Mahon. 1961. The presence of unidentified substances in the urine of psychiatric patients. *J Neuropsychiatr* 2:331–62.
171. McGinnis, W. R., et al. 2008. Discerning the Mauve Factor, pending publication *Alter Thera Health Med*.
172. Benton, D., and R. Cook. 1990. Selenium supplementation improves mood in a double-blind crossover trial. *Psychopharmacology (Berl)*. 102 (4):549–50.
173. Cordain, L., et al. 2005. Origins and evolution of the Western diet: Health implications for the 21st century. *Am J Clin Nutr* 8 (2):341–54. Review.
174. [http://www.cspinet.org/new/sugar\\_limit.html](http://www.cspinet.org/new/sugar_limit.html).
175. Kinoshita, J.; Alzheimer Research Forum. 2006. Alzheimer Research Forum live discussion: Insulin resistance: a common axis

linking Alzheimer's, depression, and metabolism? *J Alzheimers Dis* 9 (1): 89–93.

176. Yaffe, K., et al. 2004. The metabolic syndrome, inflammation, and risk of cognitive decline. *JAMA* 292 (18):2237–2242.
177. *NY Times*, January 14, 2003.
178. Silverman, D. H., et al. 2001. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. *JAMA* 286 (17):2120–127.
179. Timonen, M. et al. 2007. Insulin resistance and depressive symptoms in young adult males: Findings from Finnish military conscripts. *Psychosom Med* 69 (8):723–28.
180. Hyman, M. A. 2006. Systems biology: The gut-brain-fat cell connection and obesity. *Altern Ther Health Med* 12 (1):10–16. Review.
181. Abbott, R.D., et al. 2004. Walking and dementia in physically capable elderly men. *JAMA* 292 (12):1447–453.
182. Camaris, G., et al. 2000. The Colorado Thyroid Disease Prevalence Study. *Arch Intern Med* 160:526–34.
183. Chueire, V.B., J. H., Romaldini and L. S. Ward. 2007. Subclinical hypothyroidism increases the risk for depression in the elderly. *Arch Gerontol Geriatr* 44 (1):21–28. Epub 2006 May 5.
184. Montero-Pedrazuela, A. et al. 2006. Modulation of adult hippocampal neurogenesis by thyroid hormones: implications in depressive-like behavior. *Mol Psychiatry* 11 (4):361–71.
185. Thomsen, A. F., et al. 2005. Increased risk of developing affective disorder in patients with hypothyroidism: a register-based study. *Thyroid* 15 (7):700–7.
186. Bauer, M., A. Heinz, and P. C. Whybrow. 2002. Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain. *Mol Psychiatry* 7 (2):140–56. Review.
187. Van Boxtel, M. P., et al. 2004. Thyroid function, depressed mood, and cognitive performance in older individuals: the Maastricht Aging Study. *Psychoneuroendocrinology* 29 (7):891–98.

188. Miller, K. J., et al. 2006. Memory improvement with treatment of hypothyroidism. *Int J Neurosci* 116 (8):895–906.
189. Rack, S. K., and E. H. Makela. 2000. Hypothyroidism and depression: a therapeutic challenge. *Ann Pharmacother* 34 (10):1142–1145.
190. Bunevicius, R., et al. 1999. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. *N Engl J Med* 340 (6):424–29.
191. Abraham, G., R. Miley, and J. Lawson. 2006. T3 augmentation of SSRI resistant depression. *J Affect Disord* 91 (2–3):211–15. Epub 2006 February 17.
192. Cooper-Kazaz, R., et al. 2007. Combined treatment with sertraline and liothyronine in major depression: A randomized, double-blind, placebo-controlled trial. *Arch Gen Psychiatry* 64 (6):679–88.
193. Porterfield, S. P. 1994. Vulnerability of the developing brain to thyroid abnormalities: environmental insults to the thyroid system. *Environ Health Perspect* 102 Suppl 2:125–30. Review.
194. Otake, T., et al. 2007. Thyroid hormone status of newborns in relation to utero exposure to PCBs and hydroxylated PCB metabolites. *Environ Res* 105 (2):240–46. Epub 2007 May 8.
195. Galletti, P. M., and G. Joyet. 1958. Effect of fluorine on thyroidal iodine metabolism in hyperthyroidism. *J Clin Endocrinol Metab* 18 (10): 1102–1110.
196. Rasheed, P., and L. S. Al-Sowielem. 2003. Prevalence and predictors of premenstrual syndrome among college-aged women in Saudi Arabia. *Ann Saudi Med* 23 (6):381–87.
197. Tan, R. S., and S. J. Pu. 2001. The andropause and memory loss: is there a link between androgen decline and dementia in the aging male? *Asian J Androl* 3 (3): 169–74. Review.
198. Rich-Edwards, J.W., et al. 2007. Milk consumption and the prepubertal somatotrophic axis. *Nutr J* 6:28.
199. Milk, hormones and human health, 10/23–25/2006, Boston. *J Mammary Gland Biol Neoplasia* (2007) 12 (4):315.

200. Pape-Zambito, D. A., A. L. Magliaro, and R. S. Kensinger, 2007. Concentrations of 17beta-estradiol in Holstein whole milk. *J Dairy Sci.* 90 (7):3308–3313.
201. Osterlund, M. K., M. R. Witt, and J. A. Gustafsson. 2005. Estrogen action in mood and neurodegenerative disorders: estrogenic compounds with selective properties—the next generation of therapeutics. *Endocrine* 28 (3):235–42. Review.
202. Pluchino, N., et al. 2001. Progesterone and progestins: effects on brain, allopregnanolone and beta-endorphin. *J Steroid Biochem Mol Biol* 102 (1–5):205–13. Epub 2006 October 18. Review.
203. Schulman, M. M., et al. 2007. The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impact. *J Sex Med* 4 (4 Pt 1):1056–1069. Links.
204. Bernhardt, P. C., et al. 1998. Testosterone changes during vicarious experiences of winning and losing among fans at sporting events. *Physiol Behav* 65 (1):59–62.
205. Sternbach, H. 1998. Age-associated testosterone decline in men: clinical issues for psychiatry. *Am J Psychiatry* 155 (10):1310–1318. Review.
206. Beauchet, O. 2001. Testosterone and cognitive function: current clinical evidence of a relationship. *Eur J Endocrinol* 155 (6):773–81. Review.
207. Wu, C. Y., T. J. Yu, and M. J. Chen. 2000. Age-related testosterone level changes and male andropause syndrome. *Chang Gung Med J* 23 (6):348–53.
208. Goldstat, R., et al. 2003. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. *Menopause* 10 (5):390–98.
209. Srinivasan, V., et al. 2006. Melatonin in mood disorders. *World J Biol Psychiatry* 7 (3):138–51. Review.
210. Blackman, M. R., et al. 2007. Growth hormone and sex steroid administration in healthy aged women and men: a randomized-controlled trial. *JAMA* 288 (18):2282–2292.

211. Van Cauter, E., R. Leproult, and L. Plat. 2000. Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men. *JAMA* 284 (7):861–68.
212. Harrington, J. M. 1994. Shift work and health—a critical review of the literature on working hours. *Ann Acad Med* 23 (5):699–705. Review.
213. Scott, J. P., L. R. McNaughton, and R.C. Polman. 2006. Effects of sleep deprivation and exercise on cognitive, motor performance and mood. *Physiol Behav* 87 (2):396–408. Epub 2006 January 3.
214. Young, T., J. Skatrud, and P. E. Peppard. 2004. Risk factors for obstructive sleep apnea in adults. *JAMA* 291 (16):2013–2016. Review.
215. Elenkov, I. J., et al. 2005. Cytokine dysregulation, inflammation and well-being. *Neuroimmunomodulation* 12 (5):255–69.
216. Herbert, M. 2006. Autism: A brain disorder, or a disorder that affects the brain? *Clinical Neuropsychiatry* 2 6:354–79.
217. Ibid. 2005. Large brains in autism: The challenge of pervasive abnormality. *Neuroscientist* 11 (5):417–40. Review.
218. Vargas, D. L., et al. 2005. Neuroglial activation and neuroinflammation in the brain of patients with autism. *Ann Neurol* (2005) 57 (1):67–81. Erratum in *Ann Neurol* 57 (2):304.
219. Ashwood, P., J.Wills, J.Van de Water. 2006.The immune response in autism: a new frontier for autism research. *J Leukoc Biol* 80 (1):1–15. Review.
220. Das,U.N. 2007. Is depression a low-grade systemic inflammatory condition? *Am J Clin Nutr* 85 (6):1665–666.
221. Anisman, H., and Z. Merali. 2003. Cytokines, stress and depressive illness: brainimmune interactions. *Ann Med* 35 (1):2–11. Review.
222. Müller,N., and M. J. Schwarz. 2007. Immunological aspects of depressive disorders. *Nervenarzt* 78 (11):1261–273.
223. Bode, L., and H. Ludwig. 2003. Borna disease virus infection, a human mentalhealth risk. *Clin Microbiol Rev* 16 (3):534–45. Review.
224. Groves,D. A., and V. J. Brown. 2005.Vagal nerve stimulation: a review of its applications and potential mechanisms that mediate its clinical effects. *Neurosci Biobehav Rev* 29 (3):493–500. Review.

225. Parker, G., et al. 2006. Omega-3 fatty acids and mood disorders. *Am J Psychiatry* 163 (6):969–78. Review.
226. Blumenthal, J. A., et al. 2007. Exercise and pharmacotherapy in the treatment of major depressive disorder. *Psychosom Med* 69 (7):587–96. Epub 2007 September 10.
227. Papakostas, G. I., et al. 2005. Brain MRI white matter hyperintensities and onecarbon cycle metabolism in nongeriatric outpatients with major depressive disorder (Part II). *Psychiatry Res* 140 (3):301–7. Epub 2005 November 16.
228. Hoekstra, P. J., and R. B. Minderaa. 2005. Tic disorders and obsessive-compulsive disorder: Is autoimmunity involved? *Int Rev Psychiatry* 17 (6):497–502. Review.
229. Griffin, W. S. 2006. Inflammation and neurodegenerative diseases. *Am J Clin Nutr* 83 (2):470S–74S. Review.
230. McIntyre, R. S., et al. 2007. Should depressive syndromes be reclassified as “metabolic syndrome type II”? *Ann Clin Psychiatry* 19 (4):257–64.
231. Ibid. 2006. Managing psychiatric disorders with antidiabetic agents: Translational research and treatment opportunities. *Expert Opin Pharmacother* 7 (10):1305–1321.
232. Hunter, J. O. 1991. Food allergy—or enterometabolic disorder? *Lancet* 338 (8765):495–96.
233. King, D. S. 1981. Can allergic exposure provoke psychological symptoms? A double-blind test. *Biol Psychiatry* 16 (1):3–19.
234. Ludvigsson, J. F., et al. 2007. Coeliac disease and risk of mood disorders—a general population-based cohort study. *J Affect Disord* 99 (1–3):117–26. Epub 2006 October 6.
235. Ludvigsson, J. F., et al. 2007. Coeliac disease and risk of schizophrenia and other psychosis: A general population cohort study. *Scand J Gastroenterol* 42 (2):179–85.
236. Margutti, P., F. Delunardo, and E. Ortona. 2006. Autoantibodies associated with psychiatric disorders. *Curr Neurovasc Res* 3 (2):149–57. Review.

237. Hu, W. T., et al. 2006. Cognitive impairment and celiac disease. *Arch Neurol* 63 (10):1440–1446.
238. Wilders-Truschnig, M., et al. 2007. IgG antibodies against food antigens are correlated with inflammation and intima media thickness in obese juveniles. *Exp Clin Endocrinol Diabetes* 116 (4):241–45.
239. Liu, Y., T. Heiberg, and K. L. Reichelt. 2007. Towards a possible aetiology for depressions? *Behav Brain Funct* 14 (3):47.
240. MacDonald, T. T., and G. Monteleone. 2005. Immunity, inflammation, and allergy in the gut. *Science* 307:1920–1925.
241. Atkinson, W., et al. 2007. Food elimination based on IgG antibodies in irritable bowel syndrome: A randomised controlled trial. *Gut* 53 (10):1459–1464.
242. [www.digestive.niddk.nih.gov/statistics/statistics.htm](http://www.digestive.niddk.nih.gov/statistics/statistics.htm)
243. Benarroch, E. E. 2007. Enteric nervous system: Functional organization and neurologic
244. implications. *Neurology* 13 69(20):1953–957. Review.
245. Sandler, R. H., et al. 2000. Relief of psychiatric symptoms in a patient with Crohn's disease after metronidazole therapy. *Clin Infect Dis* 30 (1):213–14.
246. Lin, H. 2004. Small intestinal bacterial overgrowth: A framework for understanding irritable bowel syndrome *JAMA* 292:852–58.
247. Orr, W. C., S. Elsenbruch and M. J. Harnish. 2000. Autonomic regulation of cardiac function during sleep in patients with irritable bowel syndrome. *Am J Gastroenterol* 95:2865–2871.
248. Anisman, H., and Z. Merali. 2003. Cytokines, stress and depressive illness: Brain-immune interactions. *Ann Med* 35:2–11.
249. Banks, W. A., S. A. Farr, and J. E. Morley. 2002–2003. Entry of blood-borne cytokines into the central nervous system: Effects on cognitive processes. *Neuroimmunomodulation* 10:319–27.
250. Rivier, C. 1993. Effect of peripheral and central cytokines on the hypothalamic-pituitary-adrenal axis in the rat. *Ann N Y Acad Sci* 697:97–105.

251. Carlson, S. L., et al. 1987. Alternations of monoamines in specific central autonomic nuclei following immunization in mice. *Brain Behav Immun* 1:52–63.
252. Shattock, P., and P. Whiteley. 2002. Biochemical aspects in autism spectrum disorders: Updating the opioid-excess theory and presenting new opportunities for biomedical intervention. *Expert Opin Ther Targets* 6 (2):175–83. Review.
253. Pimentel, M., et al. 2006. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial. *Ann Intern Med* 145 (8):557–63.
254. Av, S. P. 2007. Hepatic encephalopathy: Pathophysiology and advances in therapy. *Trop Gastroenterol* 28 (1):4–10. Review.
255. Jansson-Nettelbladt, E., et al. 2006. Endogenous ethanol fermentation in a child with short bowel syndrome. *Acta Paediatr* 95 (4):502–4.
256. Kidd, P. M. 2002. Autism, an extreme challenge to integrative medicine. Part 2: Medical management. *Altern Med Rev* 7 (6):472–99. Review.
257. Sandler, R. H., et al. 2000. Short-term benefit from oral vancomycin treatment of regressive-onset autism. *J Child Neurol* 15 (7):429–35.
258. Parracho, H. M., et al. 2005. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. *J Med Microbiol*. 54 (Pt. 10):987–91.
259. Walsh, W. J., L. B. Glab, and M. L. Haakenson. 2004. Reduced violent behavior following biochemical therapy. *Physiol Behav* 82 (5):835–39. Ibid.
260. Benton, D. 2001. The impact of diet on antisocial, violent and criminal behaviour. *Neurosci Biobehav Rev* 31 (5):752–74. Epub 2007 March 4. Review.
261. Wakefield, A. J., et al. 2002. Review article: The concept of enterocolonic encephalopathy, autism and opioid receptor ligands. *Aliment Pharmacol Ther* 16 (4):663–74.
262. Aytac, U., and N. H. Dang. 2004. CD26/dipeptidyl peptidase IV: A regulator of immune function and a potential molecular target for

- therapy. *Curr Drug Targets Immune Endocr Metabol Disord* 4 (1):11–8. Review.
263. Mentlein, R. 1999. Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides. *Regul Pept* 85 (1):9–24. Review.
264. Shattock, P., and P. Whiteley. 2002. Biochemical aspects in autism spectrum disorders: Updating the opioid-excess theory and presenting new opportunities for biomedical intervention. *Expert Opin Ther Targets* 6 (2):175–83.
265. Ek, J., M. Stensrud, and K. L. Reichelt. 1999. Gluten-free diet decreases urinary peptide levels in children with celiac disease. *J Pediatr Gastroenterol Nutr* 29 (3):282–85.
266. Liu, Y., T. Heiberg, and K. L. Reichelt. 2007. Towards a possible aetiology for depressions? *Behav Brain Funct* 14 3:47.
267. Wakefield, A. I., et al. 2005. The significance of ileo-colonic lymphoid nodular hyperplasia in children with autistic spectrum disorder. *Eur J Gastroenterol Hepatol* 17 (8):827–36.
268. Uhlmann, V., et al. 2002. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. *Mol Pathol* 55 (2):84–90.
269. Kawashima, H., et al. 2002. Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism. *Dig Dis Sci* 45 (4):723–29.
270. Bradstreet, J. J., et al. 2004. Detection of measles virus genomic RNA in cerebrospinal fluid of children with regressive autism: A report of three cases. *J. Am Phys Surgeons* 38–45.
271. Taylor, B., et al. 1999. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. *Lancet* 353 (9169):2026–2029.
272. Millward, C., et al. 2004. Gluten- and casein-free diets for autistic spectrum disorder. *Cochrane Database Syst Rev* (2):CD003498. Review.
273. Hu, W. T., et al. 2006. Cognitive impairment and celiac disease. *Arch Neurol* 63 (10):1440–446.

274. Kalaydjian, A. E., et al. 2006. The gluten connection: The association between schizophrenia and celiac disease. *Acta Psychiatr Scand* 113 (2):82–90. Review.
275. [www.gut.bmjournals.com/cgi/content/abstract/53/10/1459](http://www.gut.bmjournals.com/cgi/content/abstract/53/10/1459) (Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial).
276. Shaheen, N., and F. Ransohoff. 2002. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: Scientific Review. *JAMA* 287: 1972–1981.
277. [www.en.wikipedia.org/wiki/List\\_of\\_top\\_selling\\_drugs](http://www.en.wikipedia.org/wiki/List_of_top_selling_drugs)
278. Ruscin, J. M., R. L. Page, and R. J. Valuck. 2002. Vitamin B12 deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. *Ann Pharmacother* 36 (5):812–16.
279. Dial, S., et al. 2005. Use of gastric acid-suppressive agents and the risk of community acquired *Clostridium difficile*-Associated Disease. *JAMA* 294 (23):2989–2995.
280. [www.cdc.gov/nchs/fastats/lcod.htm](http://www.cdc.gov/nchs/fastats/lcod.htm).
281. Plassman, H. I., et al. 2008. Prevalence of cognitive impairment without dementia in the United States. *Ann Intern Med* 148 (6):427–34.
282. Tsai, M. S., et al. 1994. Apolipoprotein E: risk factor for Alzheimer disease. *Am J Hum Genet.* 54 (4):643–49.
283. Godfrey, M. E., D. P. Wojcik, and C. A. Krone. 2003. Apolipoprotein E genotyping as a potential biomarker for mercury neurotoxicity. *J Alzheimer's Dis* 5 (3):189–95.
284. Clarkson, T. W., L. Magos, and G. Myers. 2003. The toxicology of mercury—current exposures and clinical manifestations. *N Engl J Med* 349 (18):1731–1737. Review.
285. Wojcik, D. P., et al. 2006. Mercury toxicity presenting as chronic fatigue, memory impairment and depression: diagnosis, treatment, susceptibility, and outcomes in a New Zealand general practice setting (1994–2006). *Neuro Endocrinol Lett* 27 (4):415–23.
286. Stroombergen, M. C., and R. H. Waring. 1999. Determination of glutathione S-transferase mu and theta polymorphisms in neurological disease. *Hum Exp Toxicol* 18 (3):141–45.

287. Bernardini, S., et al. 2005. Glutathione S transferase P1 \*C allelic variant increases susceptibility for late-onset Alzheimer disease: Association study and relationship with apolipoprotein E epsilon4 allele. *Clin Chem* 51 (6):944–51. Epub 2005 April 1.
288. Spalletta, G., et al. 2007. Glutathione S-transferase P1 and T1 gene polymorphisms predict longitudinal course and age at onset of Alzheimer disease. *Am J Geriatr Psychiatry* 15 (10):879–87.
289. Gundacker, C., et al. 2007. Glutathione-S-transferase polymorphism, metallothionein expression, and mercury levels among students in Austria. *Sci Total Environ* 385 (1–3):37–47. Epub 2007 Aug 22.
290. Dorszewska, J., et al. 2007. Oxidative DNA damage and level of thiols as related to polymorphisms of MTHFR, MTR, MTHFD1 in Alzheimer's and Parkinson's diseases. *Acta Neurobiol Exp (Wars)* 67 (2):113–29.
291. Rodríguez, E., et al. 2006. Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer's disease risk associated with APOE epsilon4 allele. *J Neurol* 253 (2):181–85. Epub 2005 Aug 17.
292. Mutter, J., et al. 2007. Mercury and Alzheimer's disease. *Fortschr Neurol Psychiatr* 75 (9):528–38.
293. Torres-Alanis, O., et al., 2000. Urinary excretion of trace elements in humans after sodium 2,3-dimercaptopropane-1-sulfonate challenge test. *J Toxicol Clin Toxicol* 38 (7):697–700.
294. [www.iaomt.org/articles/category\\_view.asp?intReleaseID=271&catid=30](http://www.iaomt.org/articles/category_view.asp?intReleaseID=271&catid=30)
295. Huse, D. M., et al. 2005. Burden of illness in Parkinson's disease. *Mov Disord* 20 (11):1449–1454.
296. Tanner, C. M., et al. 1999. Parkinson disease in twins: An etiologic study. *JAMA* 281 (4):341.
297. Cummings, J. L. 2007. Understanding Parkinson Disease. *JAMA* (1999) 281:376–78.
298. Ayala, A., et al. Mitochondrial toxins and neurodegenerative diseases. *Front Biosci* (12):986–1007. Review.

299. Kopal Grum, D., et al. 2006. Personality traits in miners with past occupational elemental mercury exposure. *Environ Health Perspect* 114 (2):290–96.
300. Elbaz, A., C. Dufouil and A. Alperovitch. 2007. Interaction between genes and environment in neurodegenerative diseases. *C. R. Biol* 330 (4):318–28. Epub 2007 Apr 9. Review.
301. Skaper, S. D. 2007. The brain as a target for inflammatory processes and neuroprotective strategies. *Ann N Y Acad Sci* 1122:23–34.
302. Cummings, J. L. Understanding Parkinson's disease. *JAMA* 281 (4):376–78.
303. Schapira, A. H., and C.W. Olanow. 2004. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. *JAMA* 291 (3):358–64. Review.
305. Berg, D. 2006. Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection. *J Neural Transm Suppl* (71):123–32.
306. Menke, A., et al. Blood level below 0.48 micromol/L (10 microg/dL) and mortality among U.S. adults. *Circulation* 114 (13):1388–394.
307. Lindh, U., et al. 2002. Removal of dental amalgam and other metal alloys supported by antioxidant therapy alleviates symptoms and improves quality of life in patients with amalgam-associated ill health. *Neuro Endocrinol Lett* 23 (5–6):459–82.
308. Zachi, E.C., M.A. Faria and A. Taub. 2007. Neuropsychological dysfunction related to earlier occupational exposure to mercury vapor. *Braz J Med Biol Res* Mar 40 (3):425–33.
309. Kokayi, K., et al. 2006. Findings of and treatment for high levels of mercury and lead toxicity in ground zero rescue and recovery workers and lower Manhattan residents. *Explore (NY)* 2 (5):400–7.
310. Ritvo, E. R., et al. 1986. Retinal pathology in autistic children—a possible biological marker for a subtype? *J Am Acad Child Psychiatry* 25 (1):137.

311. Megson, M.N. 2000. Is autism a G-alpha protein defect reversible with natural vitamin A? *Med Hypotheses* 54 (6):979–83.
312. Peixoto, N. C., et al. 2007. Metallothionein, zinc, and mercury levels in tissues of young rats exposed to zinc and subsequently to mercury. *Life Sci* 81 (16):1264–1271. Epub 2007 September 16.
313. <http://www.autism.com/triggers/vaccine/heavymetals.pdf>
314. Holmes, A. S., M. F. Blaxill and B. E. Haley. 2003. Reduced levels of mercury in first baby haircuts of autistic children. *Int J Toxicol* 22 (4):277–85.
315. Adams, J. B., et al. 2007. Mercury, lead, and zinc in baby teeth of children with autism versus controls. *J Toxicol Environ Health A* 70 (12):1046–1051.
316. Geier, D. A, and M. R. Geier. 2007. A prospective study of mercury toxicity biomarkers in autistic spectrum disorders. *J Toxicol Environ Health A* 70 (20):1723–1730.
317. Echeverria, D., et al. 2006. The association between a genetic polymorphism of coproporphyrinogen oxidase, dental mercury exposure and neurobehavioral response in humans. *Neurotoxicol Teratol* 28 (1):39–48.
318. Heyer, N. J., et al. 2004. Chronic low-level mercury exposure, BDNF polymorphism, and associations with self-reported symptoms and mood. *Toxicol Sci* 81 (2):354–63. Epub 2004 July 14.
319. Echeverria, D., et al. 2005. Chronic low-level mercury exposure, BDNF polymorphism, and associations with cognitive and motor function. *Neurotoxicol Teratol* 27 (6):781–96.
320. Dringen, R., and J. Hirrlinger. 2003. Glutathione pathways in the brain. *Biol Chem* 384 (4):505–16. Review.
321. Bolt, H. M., and R. Thier. 2006. Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology. *Curr Drug Metab* 7 (6):613–28. Review.
322. Dröge, W., and R. Breitkreutz. 2000. Glutathione and immune function. *Proc Nutr Soc* 59 (4):595–600. Review.

323. Atkuri, K. R., et al. 2007. N-acetylcysteine—a safe antidote for cysteine/ glutathione deficiency. *Curr Opin Pharmacol* 7 (4):355–59. Epub 2007 June 29. Review.
324. Nuttall, S., et al. 1998. Glutathione: in sickness and in health. *Lancet* 351 (9103): 645–46.
325. Shao, I., et al. 2008. Mitochondrial involvement in psychiatric disorders. *Ann Med* 40 (4):281–95.
326. Lin, M.T., and M. F. Beal. 2006. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. *Nature* 443 (7113):787–95. Review.
327. Chauhan, A., and V. Chauhan. 2006. Oxidative stress in autism. *Pathophysiology* 13 (3):171–81.
328. Bourre, J. M. 2006. Effects of nutrients (in food) on the structure and function of the nervous system: Update on dietary requirements for brain. Part 2: macronutrients. *J Nutr Health Aging* 10 (5):386–99. Review.
329. Razmara, A., et al. 2007. Estrogen suppresses brain mitochondrial oxidative stress in female and male rats. *Brain Res* 1176:71–81. Epub 2007 Aug 24.
330. Psarra, A. M., S. Solakidi, and C. E. Sekeris. 2006. The mitochondrion as a primary site of action of steroid and thyroid hormones: Presence and action of steroid and thyroid hormone receptors in mitochondria of animal cells. *Mol Cell Endocrinol* 246 (1–2):21–33. Epub 2006 Jan 4. Review.
331. Psarra, A. M., S. Solakidi, and C. E. Sekeris. 2006. The mitochondria as a primary site of action of regulatory agents involved in neuroimmunomodulation. *Ann NY Acad Sci* 1088:12–22. Review.
332. Corda, S., et al. 2001. Rapid reactive oxygen species production by mitochondria in endothelial cells exposed to tumor necrosis factor- $\alpha$  is mediated by ceramide. *Am J Respir Cell Mol Biol* 24 (6):762–68.
333. Yin, Z., et al. 2007. Methylmercury induces oxidative injury, alterations in permeability and glutamine transport in cultured astrocytes. *Brain Res* 1131(1):1–10. Epub 2006 December 19.
334. Lombard, J. 1998. Autism: A mitochondrial disorder? *Med Hypotheses* 50 (6):497–500. Review.

335. Clark-Taylor, T., and B. E. Clark-Taylor. 2004. Is autism a disorder of fatty acid metabolism? Possible dysfunction of mitochondrial beta-oxidation by long chain acyl-CoA dehydrogenase. *Med Hypotheses* 62 (6):970–75.
336. Leuner, K., et al. 2007. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease? *Antioxid Redox Signal* 9 (10):1659–1675. Review.
337. Yamashita, H., and M. Matsumoto. 2007. Molecular pathogenesis, experimental models and new therapeutic strategies for Parkinson's disease. *Regen Med* 2 (4):447–55.
338. Muqit, M. M., S. Gandhi, and N.W. Wood. 2006. Mitochondria in Parkinson disease: back in fashion with a little help from genetics. *Arch Neurol* 63 (5):649–54.
339. Moretti, A., A. Gorini, and R. F. Villa. 2003. Affective disorders, antidepressant drugs and brain metabolism. *Mol Psychiatry* 8 (9):773–85. Review.
340. Kato, T. 2007. Mitochondrial dysfunction as the molecular basis of bipolar disorder: Therapeutic implications. *CNS Drugs* 21 (1):1–11. Review.
341. Trushina, E., and C.T. McMurray. 2007. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. *Neuroscience* 145 (4):1233–1248. Epub 2007 February 14. Review.
342. Villmann, C., and C. M. Becker. 2007. On the hypes and falls in neuroprotection: Targeting the NMDA receptor. *Neuroscientist* 13 (6):594–615. Epub 2007 October 2.
343. Mattson, M. P. 2007. Calcium and neurodegeneration. *Aging Cell* 6 (3):337–50. Epub 2007 February 28. Review.
344. Baur, J. A., et al. 2006. Resveratrol improves health and survival of mice on a highcalorie diet. *Nature* 444 (7117):337–42. Epub 2006 November 1.
345. Petersen, K. F., and G. I. Shulman. 2006. Etiology of insulin resistance. *Am J Med* 119 (5) Suppl 1:S10–16. Review.

346. Petersen, K. F., et al. 2004. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. *N Engl J Med* 350 (7):664–71.
347. Lagouge, M., et al. 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. *Cell* (Epub ahead of print).
348. Hipkiss, A. R. 2008. Energy metabolism, altered proteins, sirtuins and ageing: converging mechanisms? *Biogerontology* 9 (1):49–55.
349. Whitmer, R.A. 2007. Type 2 diabetes and risk of cognitive impairment and dementia. *Curr Neurol Neurosci Rep* 7 (5):373–80. Review.
350. McIntyre, R. S., et al. 2007. Should depressive syndromes be reclassified as “metabolic syndrome Type II”? *Ann Clin Psychiatry* 19 (4):257–64. Review.
351. Binienda, Z., et al. 2005. L-carnitine and neuroprotection in the animal model of mitochondrial dysfunction. *Ann N Y Acad Sci* (1053):174–82.
352. Ames, B.N. 2003. The metabolic tune-up: Metabolic harmony and disease prevention. *J Nutr* 133 (5 Suppl 1):1554S–1548S.
353. Liu, J., et al. 2002. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: Partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic acid. *Proc Natl Acad Sci USA* 99 (4):2356–2361.
354. Liu, J., and B. N. Ames. 2005. Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer’s disease, and Parkinson’s disease. *Nutr Neurosci* 8 (2):67–89.
355. Shea, T. B. 2007. Effects of dietary supplementation with N-acetylcysteine, acetyl-L-carnitine and S-adenosyl methionine on cognitive performance and aggression in normal mice and mice expressing human ApoE4. *Neuromolecular Med* 9 (3):264–69.
356. Engelhart, M. J., et al. 2002. Dietary intake of antioxidants and risk of Alzheimer disease. *JAMA* 287 (24):3223–3229.
357. Dai, Q., et al. 2006. Fruit and vegetable juices and Alzheimer’s disease: The Kame Project. *Am J Med* 119 (9):751–59.

358. Mythri, R. B., et al. 2007. Mitochondrial complex I inhibition in Parkinson's disease: How can curcumin protect mitochondria? *Antioxid Redox Signal* 9 (3):399–408.
359. Beal, M. F. 2004. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. *J Bioenerg Biomembr* 36 (4):381–86. Review.
360. Shults, C.W., et al. 2002. Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline. *Arch Neurol* 59 (10):1541–1550.
361. Young, A. J., et al. 2007. Coenzyme Q10: A review of its promise as a neuroprotectant. *CNS Spectr* 12 (1):62–68. Review.
362. Rosenberg, R. N. 2002. Mitochondrial therapy for Parkinson disease. *Arch Neurol* 59 (10):1523.
363. Littarru, G. P., and P. Langsjoen. 2007. Coenzyme Q10 and statins: Biochemical and clinical implications. *Mitochondrion* 7 Suppl:S168–74. Epub 2007 March 27. Review.
364. Sewright, K. A., P. M. Clarkson, and P. D. Thompson. 2007. Statin myopathy: Incidence, risk factors, and pathophysiology. *Curr Atheroscler Rep* 9 (5):389–96.
365. Draeger, A., et al. 2006. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. *J Pathol* 210 (1):94–102.
366. Phillips, P. S., et al. 2002. Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. *Ann Intern Med* 137 (7):581–85.
367. [www.news.bbc.co.uk/2/hi/health/3931157.stm](http://www.news.bbc.co.uk/2/hi/health/3931157.stm)
368. Beal, M. F. 2003. Bioenergetic approaches for neuroprotection in Parkinson's disease. *Ann Neurol Suppl* 3:S39–47; discussion S47–48.
369. Moreira, P. I., et al. 2007. Lipoic acid and N-acetyl cysteine decrease mitochondrial related oxidative stress in Alzheimer disease patient fibroblasts. *J Alzheimers Dis* 12 (2):195–206.
370. McGinnis, W. R. 2005. Oxidative stress in autism. *Altern Ther Health Med* 11 (1):19.

371. Lantz, P. M., et al. 1998. Socioeconomic Factors, Health Behaviors, and Mortality: Results From a Nationally Representative Prospective Study of US Adult, *JAMA* 279:1703–1708.
372. Karasek, R. 2006. The stress-disequilibrium theory: chronic disease development, low social control, and physiological de-regulation. *Med Lav* 97 (2):258–71. Review.
373. Sapolsky, Robert M. *Why Zebras Don't Get Ulcers: An Updated Guide to Stress, Stress-Related Diseases, and Coping* (New York: Holt/Owl, 1994; 2004).
374. McEwen, B. S. 1998. Protective and damaging effects of stress mediators. *N Engl J Med* 338 (3):171–79. Review.
375. Uno, H., et al. 1994. Neurotoxicity of glucocorticoids in the primate brain. *Horm Behav* 28 (4):336–48.
376. Gillespie, C. F., and C. B. Nemeroff. 2005. Hypercortisolemia and depression. *Psychosom Med* 67 Suppl 1:S26–28. Review.
377. Pruessner, J. C., et al. 2005. Self-esteem, locus of control, hippocampal volume, and cortisol regulation in young and old adulthood. *Neuroimage* 28 (4):815–26. Epub 2005 July 14.
378. Lupien, S. I., et al. 2007. The effects of stress and stress hormones on human cognition: Implications for the field of brain and cognition. *Brain Cogn* 65 (3):209–37. Epub 2007 April 26.
379. Yehuda, R. 2002. Post-traumatic stress disorder. *N Engl J Med* 346 (2):108–14. Review.
380. McEwen, B. S. 2006. Protective and damaging effects of stress mediators: central role of the brain. *Dialogues Clin Neurosci* 8 (4):367–81. Review.
381. Brown, D. P. 2007. The energy body and its functions: Immunosurveillance, longevity, and regeneration. *Ann N Y Acad Sci*. Epub 2007 September 28.
382. Starkman, M. N., et al. 1992. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome. *Biol Psychiatry* 32 (9):756–65.

383. Starkman, M. N., et al. 1999. Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease. *Biol Psychiatry* 46 (12):1595–1602.
384. Ibid., et al. 2003. Improvement in learning associated with increase in hippocampal formation volume. *Biol Psychiatry* 53 (3):233–38.
385. Cameron, H. A., and R. D. McKay. 1999. Restoring production of hippocampal neurons in old age. *Nat Neurosci* 2 (10):894–97.
386. Hansen, A. L., B. H. Johnsen, and J. F. Thayer. 2003. Vagal influence on working memory and attention. *Int J Psychophysiol* 48 (3):263–74.
387. Chahine, T., et al. 2007. Particulate air pollution, oxidative stress genes, and heart rate variability in an elderly cohort. *Environ Health Perspect* 115 (11):1617–1622.
388. Sloan, R. P., et al. 2007. RR interval variability is inversely related to inflammatory markers: The CARDIA study. *Mol Med* 13 (3–4):178–84.
389. Pavlov, V. A., and K. J. Tracey. 2005. The cholinergic anti-inflammatory pathway. *Brain Behav Immun* 19 (6):493–99. Review.
390. Theise, N. D., and R. Harris. 2006. Postmodern biology: (adult) (stem) cells are plastic, stochastic, complex, and uncertain. *Handb Exp Pharmacol* (174):389–408. Review.
391. Lamming, D. W., J. G. Wood, and D. A. Sinclair. 2004. Small molecules that regulate lifespan: Evidence for xenohormesis. *Mol Microbiol* 53 (4):1003–1009. Review.
392. Yun, A. I., and J. D. Doux. 2007. Unhappy meal: How our need to detect stress may have shaped our preferences for taste. *Med Hypotheses* 69 (4):746–51.
393. Bazar, K. A., et al. 2006. Obesity and ADHD may represent different manifestations of a common environmental oversampling syndrome: A model for revealing mechanistic overlap among cognitive, metabolic, and inflammatory disorders. *Med Hypotheses* 66 (2):263–69. Review.
394. Kallio, P., et al. 2007. Dietary carbohydrate modification induces alterations in gene expression in abdominal subcutaneous adipose tissue in persons with the metabolic syndrome: The FUNGENUT Study. *Am J Clin Nutr* 85 (5):1417–1427.

395. WHO Initiative on Depression in Public Health, [http://www.who.int/mental\\_health/management/depression/depressioninph/en/](http://www.who.int/mental_health/management/depression/depressioninph/en/). Accessed March 10, 2008.
396. Palpant, R. G., R. Steimnitz, T. H. Bornemann, and K. Hawkins. 2006. The Carter Center Mental Health Program: Addressing the public health crisis in the field of mental health through policy change and stigma reduction. *Preventing Chronic Disease* 3:1–6.
397. Philpot, W. *Brain Allergies: The Psychonutrient and Magnetic Connections* (New York: McGraw-Hill, 2000).
398. Campbell, T.C. 1990. A study on diet, nutrition and disease in the People's Republic of China. Part I. *Bol Asoc Med P R* 82 (3):132–34.
399. Campbell, T.C. 1990. A study on diet, nutrition and disease in the People's Republic of China. Part II. *Bol Asoc Med P R* 82 (7):316–18. Review.
400. Bourre, J. M. 2006. Effects of nutrients (in food) on the structure and function of the nervous system: Update on dietary requirements for the brain. Part 1: Micronutrients. *J Nutr Health Aging* 10 (5):377–85. Review.
401. Ibid., 2006. Part 2: Macronutrients. *J Nutr Health Aging* 10 (5):386–99. Review. 1. Galvin, J.A., et al. 2006. The relaxation response: reducing stress and improving cognition in healthy aging adults. *Complement Ther Clin Pract* 12 (3):186–91.
402. Hankey, A. 2006. Studies of advanced stages of meditation in the Tibetan Buddhist and vedic traditions. I: A comparison of general changes. *Evid Based Complement Alternat Med* 3 (4):513–21.
403. Davidson, R. J., et al. 2003. Alterations in brain and immune function produced by mindfulness meditation. *Psychosom Med* 65 (4):564–70.
404. Gordon, J. S. 2006. Healing the wounds of war: Gaza diary. *Altern Ther Health Med* 12 (1):18–21.
405. Verghese, J., et al. 2003. Leisure activities and the risk of dementia in the elderly. *N Eng J Med* 348 (25):2508–2516.

406. Galletti, P. M., and G. Joyet. 1958. Effect of fluorine on thyroidal iodine metabolism in hyperthyroidism. *J Clin Endocrinol Metab* 18 (10):1102–1110.
407. Xanthis, A., et al. 2007. Advanced glycosylation end products and nutrition—a possible relation with diabetic atherosclerosis and how to prevent it. *J Food Sci* 72 (8):R125–29.
408. Persky, V. W., et al. 2002. Effect of soy protein on endogenous hormones in postmenopausal women. *Am J Clin Nutr* 75 (1):145–53. Erratum in *Am J Clin Nutr* 76 (3):695.
409. Galletti, P. M., and G. Joyet. 1958. Effect of fluorine on thyroidal iodine metabolism in hyperthyroidism. *J Clin Endocrinol Metab* 18 (10):1102–1110.
410. Gaby, A. R. 2004. Sublaboratory hypothyroidism and the empirical use of *Armour thyroid*. *Altern Med Rev* 9 (2):157–79.
411. Goglia, F. 2005. Biological effects of 3,5-diiodothyronine (T[2]). *Biochemistry (Mosc)* 70 (2):164–72.
412. Smith, J. K. 1999. Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. *JAMA* 281 (18):1722–1727.
413. Church, T. S. 2003. Reduction of C-reactive protein levels through use of a multivitamin. *Am J Med* 115 (9):702–7.
414. Gortner, E. M., S. S. Rude, and J. W. Pennebaker. 2006. Benefits of expressive writing in lowering rumination and depressive symptoms. *Behav Ther* 37 (3):292–303.
415. Ernst, E., et al. 2001. Mind-body therapies: are the trial data getting stronger? *Altern Ther Health Med* 13 (5):62–64.
416. Cohen, S., D. Janicki-Deverts, and G. E. Miller. 2001. Psychological stress and disease. *JAMA* 298 (14):1685–1687.